Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -40.5% | +8.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -40.5% over three years. Forward estimates point to Revenue at +8.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Bio-Techne Corporation NASDAQ:TECH | $11.44B | $72.80 | Overvalued | 78.3 | +26.24% |
Repligen Corporation NASDAQ:RGEN | $10.73B | $167.79 | Overvalued | 142.4 | +11.34% |
Bio-Rad Laboratories, Inc. NYSE:BIO | $9.85B | $366.36 | Fairly Valued | 45.4 | +21.45% |
Neogen Corporation NASDAQ:NEOG | $2.45B | $11.23 | Overvalued | -3.3 | +98.92% |
Azenta, Inc. NASDAQ:AZTA | $2.00B | $45.65 | Overvalued | -5.9 | +62.14% |
BioLife Solutions, Inc. NASDAQ:BLFS | $1.89B | $38.61 | Overvalued | -119.9 | +58.37% |
Pacific Biosciences of California, Inc. NASDAQ:PACB | $611.98M | $1.96 | Not rated | -3.3 | +3.98% |
Standard BioTools Inc. NASDAQ:LAB | $279.27M | $0.71 | Not rated | -3.5 | -55.47% |
Continue the stock analysis
Jump to another research area for this company.